|
|
|
| The Development Situation and Suggestions of mmune Cell Therapy Industry |
Yan SU1,Li XU1,Li-wei WANG2,Yue WANG1,Ping XU1,*( ) |
1 Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China
2 Bureau of Frontier Sciences and Education, Chinese Academy of Sciences, Beijing 100864, China |
|
|
|
Abstract Immunotherapy has been successfully applied in the treatment of many kinds of tumors, and significantly improved the quality of life of patients. Immune cell therapy is one of the focus directions in the development of immunotherapy. The development of immune cell therapy has gone through the stage of development of non-specific immunity to non-differentiated specific immunity and to differentiated specific immunity. Several immune cell therapy products have launched, and the industrial system has been preliminarily formed, including treatment/drug development and related services/equipment production. By analyzing the immune cell therapy industry development situation at home and abroad and the technology development bottleneck, main problems of the development of the industry in China are pointed, some suggestions were put forward so as to provide reference for the development of immune cell therapy industry in China.
|
|
Received: 23 January 2018
Published: 05 June 2018
|
|
|
|
Corresponding Authors:
Ping XU
E-mail: xuping@sibs.ac.cn
|
|
|
| [1] |
Kantoff P W, Higano C S, Shore N D , et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New England Journal of Medicine, 2010,363(5):411-422.
doi: 10.1016/S0022-5347(11)60154-7
|
|
|
| [2] |
Barbuto J A, Ensina L F, Neves A R , et al. Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunology Immunotherapy, 2004,53(12):1111-1118.
doi: 10.1007/s00262-004-0551-7
pmid: 15185011
|
|
|
| [3] |
Porter D L, Levine B L, Kalos M , et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. New England Journal of Medicine, 2011,365(8):725-733.
doi: 10.1056/NEJMoa1103849
pmid: 21830940
|
|
|
| [4] |
Kumar C, Kohli S, Chiliveru S , et al. A retrospective analysis comparing APCEDEN (?) dendritic cell immunotherapy with best supportive care in refractory cancer . Immunotherapy, 2017,9(11):889-897.
doi: 10.2217/imt-2017-0064
pmid: 28838282
|
|
|
| [5] |
付贤 . 树突状细胞在去势抵抗前列腺癌免疫治疗中的研究进展. 国际泌尿系统杂志, 2014,34(4):559-562.
doi: 10.3760/cma.j.issn.1673-4416.2014.04.028
|
|
|
| [5] |
Fu X . Advances in research on dendritic cells in castration-resistant prostate cancer immunotherepy. International Journal of Urology and Nephrology, 2014,34(4):559-562.
doi: 10.3760/cma.j.issn.1673-4416.2014.04.028
|
|
|
| [6] |
Harris D T, Kranz D M . Adoptive T cell therapies: a comparison of T cell receptors and chimeric antigen receptors. Trends in Pharmacological Sciences, 2016,37(3):220-230.
doi: 10.1016/j.tips.2015.11.004
pmid: 26705086
|
|
|
| [7] |
陆虹旻, 李林凤, 高建新 . 基于树突细胞的肿瘤疫苗研究进展. 胃肠病学, 2016,21(5):257-262.
|
|
|
| [7] |
Lu H M, Li L F, Gao J X . Advances in research on dendritic cell-based tumor vaccine. Chinese Journal of Gastroenterology, 2016,21(5):257-262.
|
|
|
| [8] |
何永跃 . 胶质瘤免疫治疗与血脑屏障. 国际神经病学神经外科学杂志, 2017,44(1):68-70.
doi: 10.16636/j.cnki.jinn.2017.01.016
|
|
|
| [8] |
He Y Y . Glioma immunotherapy and blood-brain barrier. Journal of International Neurology and Neurosurgery, 2017,44(1):68-70.
doi: 10.16636/j.cnki.jinn.2017.01.016
|
|
|
| [9] |
Kershaw M H, Westwood J A, Parker L L , et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clinical Cancer Research, 2006,12(20):6106-6115.
doi: 10.1158/1078-0432.CCR-06-1183
pmid: 17062687
|
|
|
| [10] |
Park J R, Digiusto D L, Slovak M , et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with Neuroblastoma. Molecular Therapy, 2007,15(4):825-833.
doi: 10.1038/sj.mt.6300104
pmid: 17299405
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
